Skip to main content
Clinical Trials/NCT06352307
NCT06352307
Recruiting
Not Applicable

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country1,500 target enrollmentApril 9, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arrhythmogenic Cardiomyopathy
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
1500
Locations
1
Primary Endpoint
Change in the incidence of mortality rate
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Detailed Description

This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

Registry
clinicaltrials.gov
Start Date
April 9, 2024
End Date
August 31, 2032
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years old.
  • The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.
  • Patients or their families agreed to participate in the study and authorized informed consent.

Exclusion Criteria

  • Incomplete clinical data.
  • Do not agree to the inclusion or refuse to authorize the informed consent.

Outcomes

Primary Outcomes

Change in the incidence of mortality rate

Time Frame: At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year.

The survival status will be obtained from the medical records and phone calls to patients or their family members.

Study Sites (1)

Loading locations...

Similar Trials